The abstract is read at the publisher; the summary is JClub's.
AAV6.2FF enabled sustained SARS-CoV-2 neutralizing IgG1 expression in human monocyte-derived dendritic cells, with SFFV-driven HC-P2A-LC producing durable antibody levels.
- Why it matters: Pulmonary monoclonal antibody therapy is limited by poor diffusion from blood to airway epithelium, motivating localized delivery that supports full antibody expression in respiratory cell types.
- What they did: The study tested AAV vectors in A549 ATII-like cells, moDCs, primary ATII organoids, and airway epithelial ALI cultures, comparing AAV6.2FF versus AAV6 and single HC-P2A-LC versus separate HC + LC delivery.
- The result: AAV6.2FF-HC-P2A-LC increased IgG1 in A549 and moDCs, showed efficient high-level expression in ATII organoids and lung fibroblasts, and in ALI airway epithelium produced lower but stable IgG1 that reduced SARS-CoV-2 propagation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.